With nearly two months of Prozac sales data available, the erosion in prescriptions is the most severe ever for a blockbuster product in our industry,
Our strong bottom-line results in the first quarter reflect the execution on our commitment to grow sales at a faster rate than our expenses.
Our overall growth for the next several quarters will be generated from newer product sales, line extensions of existing products and recent product launches, ... As a result, we will rely less on Prozac sales growth.
As our product line continues to become more diversified, we have become less dependent on Prozac performance. Major products introduced in the last five years accounted for fully one-third of our sales in 1999 and had a combined growth rate of 41 percent during the year.
As we expected, the second half of 2005 is bringing stronger sales and earnings growth,